Doble B, Finkelstein EA, Tian Y, et al. - For patients with polypoidal choroidal vasculopathy (PCV), researchers sought to determine the incremental cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy (combination therapy) vs ranibizumab monotherapy. For this investigation, all candidates were given 0.5 mg of intravitreal ranibizumab once every 4 weeks for the first 3 months. Standard fluence (50 J/cm³) photodynamic therapy with 6-mg/m² verteporfin was administered once during the first 3 months and thereafter as needed for candidates receiving combination therapy. Findings revealed that combination therapy generated slightly higher quality-adjusted life-years (7.87 vs 7.85) at roughly equal lifetime costs during a lifetime horizon. Combination therapy may not be cost-effective for a 10-year horizon. The results suggested that PCV patients should consider combination therapy with ranibizumab as an alternative to standard care.